TC
EBS icon

TwinBeech Capital’s Emergent Biosolutions EBS Stock Holding History

TwinBeech Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-92,098
Closed -$677K – 700
2023
Q2 		$677K Buy
92,098
+38,946
+73% +$361K 0.01% 487
2023
Q1 		$551K Sell
53,152
-22,006
-29% -$266K 0.01% 500
2022
Q4 		$888K Buy
+75,158
New +$1.16M 0.02% 528
2022
Q1 		– Sell
-7,640
Closed -$332K – 563
2021
Q4 		$332K Buy
+7,640
New +$346K 0.02% 472

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TwinBeech Capital's EBS Position: Q3 2023 in Review

TwinBeech Capital sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 92,098 shares — an estimated $677K sold.

TwinBeech Capital first reported a position in EBS in Q4 2021 and held it in 4 quarters. The position peaked at $888K in Q4 2022. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • TwinBeech Capital reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • TwinBeech Capital sold 92,098 Emergent Biosolutions shares in Q3 2023, an estimated $677K.
  • TwinBeech Capital first reported a position in Emergent Biosolutions in Q4 2021 and held it in 4 quarters.
  • TwinBeech Capital's Emergent Biosolutions position peaked at $888K in Q4 2022.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on TwinBeech Capital's 13F filing for Q3 2023, filed 14 Nov 2023.